Tenax Therapeutics (TENX) closed at $1.79 on October 30, 2026, down 3.8% from the previous close, on volume of 798,804 shares (30-day average 2,341,480).
Data as of October 30, 2026.
30-Oct-2026
Globe Newswire (Fri, 30-Oct 8:18 PM ET)
Newsfile (Fri, 30-Oct 7:24 PM ET)
PRNewswire (Fri, 30-Oct 12:00 PM ET)
ACCESS Newswire (Fri, 30-Oct 11:50 AM ET)
Business Wire (Fri, 30-Oct 11:00 AM ET)
PRNewswire (Fri, 30-Oct 9:06 AM ET)
Business Wire (Fri, 30-Oct 9:00 AM ET)
Globe Newswire (Thu, 29-Oct 6:10 PM ET)
Newsfile (Thu, 29-Oct 5:58 PM ET)
Business Wire (Thu, 29-Oct 3:46 PM ET)
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Tenax Therapeutics trades on the NASDAQ stock market under the symbol TENX.
As of October 30, 2026, TENX stock price declined to $1.79 with 798,804 million shares trading.
TENX has a beta of 0.52, meaning it tends to be less sensitive to market movements. TENX has a correlation of 0.00 to the broad based SPY ETF.
TENX has a market cap of $47.48 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, TENX traded as high as $61.20 and as low as $1.31.
The top ETF exchange traded funds that TENX belongs to (by Net Assets): IWM, VTI, IWN, VXF, VTWO.
TENX has underperformed the market in the last year with a return of -76.0%, while the SPY ETF gained +12.3%. In the last 3 month period, TENX fell short of the market, returning -88.1%, while SPY returned +2.1%. However, in the most recent 2 weeks TENX has outperformed the stock market by returning +31.6%, while SPY returned -1.0%.
TENX support price is $1.75 and resistance is $1.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TENX shares will trade within this expected range on the day.
